Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02690532 · ClinicalTrials.gov registry record
Gut Permeability Assessment in Celiac and Gluten Sensitive Children
A clinical trial of Celiac Disease, sponsored by Mayo Clinic.
- Completed
- Registry status
- 40
- Enrollment target
- 1
- Study location
NCT02690532: Completed study of Celiac Disease, sponsored by Mayo Clinic.
NCT02690532 is a study of Celiac Disease that has completed, run by Mayo Clinic. The registered enrollment target is 40 participants, below the 1,978-participant average among 24 other Celiac Disease trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02690532, a study of Celiac Disease, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will assess the effect of gluten on gut barrier function. Investigators at the Mayo Clinic have developed a new gut permeability test using rhamnose (sugar \& water solution), and are hoping to prove its effectiveness in a clinical setting.
Primary Outcome
Assess the effect of gluten on gut permeability in children at high risk of developing celiac disease or gluten sensitivity
Conditions Studied
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2016-03 |
| Est. Completion | 2018-08-01 |
What the finished NCT02690532 record still lists
NCT02690532 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 1,978-participant average among 24 other Celiac Disease trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Celiac Disease appearing as the primary indexed condition, and to 0 interventions.
NCT02690532 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT02690532 about?
NCT02690532 is a clinical study titled "Gut Permeability Assessment in Celiac and Gluten Sensitive Children". This study will assess the effect of gluten on gut barrier function. Investigators at the Mayo Clinic have developed a new gut permeability test using rhamnose (sugar \& water solution), and are hoping to prove its effectiveness in a clinical setting.
What is the current status of trial NCT02690532?
This trial is currently completed. The enrollment target is 40 participants. The study started on 2016-03. Estimated completion is 2018-08-01.
What conditions does trial NCT02690532 study?
This clinical trial studies the following conditions: Celiac Disease.
Who is sponsoring clinical trial NCT02690532?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02690532 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Celiac Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02690532's enrollment target sits among peer trials
40 19th of 24 higher than 4 of 24 other Celiac Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Celiac Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Tissue Destruction and Healing in Celiac Disease
RECRUITING · NA
-
Celiac Disease Genomic Environmental Microbiome and Metabolomic Study
RECRUITING
-
A First-in-human Study to Evaluate the Safety and Tolerability of HB-2121 as a Diagnostic for Celiac Disease
RECRUITING · Phase 1
-
Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research
RECRUITING
-
Immune Responses to Gluten
RECRUITING · NA
-
Double Blind, Placebo-controlled Trial to Establish Safety and Efficacy of Ritlecitinib in Celiac Disease Patients in Remission
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia